Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Novatim
Los Angeles, California, United Statesen.novatim-zj.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Novatimm is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of infectious diseases and cancer. The company's lead program, TIMM-001, is a macrophage-targeted agent designed to modulate the immune system's response to chronic viral infections and malignant tumors. By specifically targeting macrophages, Novatimm aims to overcome the immune evasion mechanisms employed by pathogens like HIV and various solid tumors. The company's research is based on pioneering work in macrophage biology and its role in disease progression. Novatimm continues to advance its pipeline through early-stage clinical trials to validate its unique therapeutic approach.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small moleculeImmunotherapy
- Industry
- Biotech
Beyond the preview
Go deeper on Novatim.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novatim.